16:02 Dec 20
Pfizer Ltd.
Sector Pharmaceuticals & Biotechnology
Industry Pharmaceuticals
Pfizer Ltd.
Industry Pharmaceuticals
16:02 Dec 20
Quality
68/100
High Financial Strength
Valuation
29/100
Expensive Valuation
Technical
43/100
Technically Neutral
Strength
6
Weakness
6
Opportunity
1
Threats
0
33.24 %
ROE %
27.21 %
ROA %
135.07
EPS
301.94
BVPS
40.85 %
Net Profit Margin
| Nov 2006 | Nov 2007 | Nov 2008 | ||
|---|---|---|---|---|
| Net Sales | 733.7 | 735.6 | 733.2 | |
| Operating Expenses + | 568.02 | 579.1 | 580.77 | |
| Raw Material | 246.68 | 238.95 | 271.31 | |
| Increase Decrease in Cost | -10.25 | 4.77 | -22.49 | |
| Other Manufacturing Expense | 26.8 | 29.05 | 30.99 | |
| Employee Cost | 102.34 | 101.7 | 102.1 | |
| Miscellaneous Expenses | 417.35 | 383.81 | 348.78 | |
| Operating Profit | 165.68 | 156.5 | 152.43 | |
| Other Income | 33.47 | 319.87 | 66.02 | |
| Depreciation | 13.07 | 9.58 | 11.12 | |
| Interest | 0.07 | 0.02 | 0 | |
| Profit before tax and exceptio.. | 186.01 | 466.76 | 207.33 | |
| Exceptional Items | 0 | 0 | 0 | |
| PBT | 186.01 | 466.76 | 207.33 | |
| Provision for Taxation | 56.31 | 111.34 | 119.56 | |
| Net Profit | 106.33 | 340 | 299.57 | |
| NET Profit after MI | 106.33 | 340 | 299.57 | |
| EPS | 35.63 | 113.93 | 100.38 | |
| Operating Profit Margin (%) | 22.58 | 21.28 | 20.79 | |
| Net Profit Margin (%) | 14.49 | 46.22 | 40.86 |
ShareHolding
Promoter
FII
Public
Mutual Funds
Other Institutions
All Data in Percentage (%)
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Promoter | 63.90 | 63.90 | 63.90 | 63.90 | 63.90 |
| FII | 3.50 | 3.20 | 3.30 | 3.00 | 2.80 |
| MF | 10.40 | 8.30 | 7.70 | 7.60 | 7.40 |
| Public | 16.50 | 17.00 | 17.40 | 17.90 | 18.20 |
| Others | 0.00 | 0.10 | 0.10 | 0.00 | 0.10 |
| Others | 5.70 | 7.50 | 7.60 | 7.60 | 7.60 |
| Shareholder | Shares | Holding % |
|---|
Download Our App On:
